ATE337016T1 - Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen - Google Patents

Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Info

Publication number
ATE337016T1
ATE337016T1 AT00931720T AT00931720T ATE337016T1 AT E337016 T1 ATE337016 T1 AT E337016T1 AT 00931720 T AT00931720 T AT 00931720T AT 00931720 T AT00931720 T AT 00931720T AT E337016 T1 ATE337016 T1 AT E337016T1
Authority
AT
Austria
Prior art keywords
orally administered
bioavailability
compositions
increase
pharmaceutical compounds
Prior art date
Application number
AT00931720T
Other languages
English (en)
Inventor
Johannes Henricus Ma Schellens
Alfred Hermanus Schinkel
Original Assignee
Cancer Res Ventures Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Ventures Ltd filed Critical Cancer Res Ventures Ltd
Application granted granted Critical
Publication of ATE337016T1 publication Critical patent/ATE337016T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00931720T 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen ATE337016T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1012066 1999-05-17
NL1012481 1999-06-30

Publications (1)

Publication Number Publication Date
ATE337016T1 true ATE337016T1 (de) 2006-09-15

Family

ID=26642978

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00931720T ATE337016T1 (de) 1999-05-17 2000-05-17 Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
AT06117838T ATE484295T1 (de) 1999-05-17 2000-05-17 Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06117838T ATE484295T1 (de) 1999-05-17 2000-05-17 Zubereitungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Country Status (10)

Country Link
US (2) US7030132B2 (de)
EP (2) EP1749540B1 (de)
AT (2) ATE337016T1 (de)
AU (1) AU4955200A (de)
CY (1) CY1105795T1 (de)
DE (2) DE60030283T2 (de)
DK (1) DK1189637T3 (de)
ES (1) ES2270834T3 (de)
PT (1) PT1189637E (de)
WO (1) WO2000069390A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU4955200A (en) * 1999-05-17 2000-12-05 Cancer Research Ventures Limited A method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
HU0100947D0 (en) * 2001-03-02 2001-05-28 Solvo Kft Screening system based on expression of abcg2 half transporter protein in an expression system free of other abc-transporters, abcg2 homodimers
US7169763B2 (en) * 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers
MXPA06015148A (es) * 2004-07-01 2007-08-21 Netherlands Cancer Inst Combinacion que comprende un inhibidor de bcrp y 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida.
US8518022B2 (en) 2004-08-27 2013-08-27 Medimetrics Personalized Drug Delivery, Inc. Electronically and remotely controlled pill and system for delivering at least one medicament
US20090234331A1 (en) * 2004-11-29 2009-09-17 Koninklijke Philips Electronics, N.V. Electronically controlled pill and system having at least one sensor for delivering at least one medicament
WO2006065125A1 (en) * 2004-12-16 2006-06-22 Het Nederlands Kanter Instituut Means and methods for determining and/or influencing transportation
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer
CN101945613B (zh) * 2008-02-18 2014-08-13 皇家飞利浦电子股份有限公司 为患者用药
CN101983029B (zh) * 2008-03-31 2015-01-14 皇家飞利浦电子股份有限公司 制备包括传感器的可吞服胶囊的方法
WO2009134405A2 (en) 2008-04-30 2009-11-05 Siemens Medical Solutions Usa, Inc. Novel substrate based pet imaging agents
CN102065930B (zh) * 2008-06-19 2013-05-22 皇家飞利浦电子股份有限公司 用于在潮湿环境下传递粉末状药物的装置
JP5670326B2 (ja) * 2008-06-25 2015-02-18 メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ 複数の薬剤リザーバを有する電子ピル
JP5497176B2 (ja) 2009-08-12 2014-05-21 コーニンクレッカ フィリップス エヌ ヴェ 圧縮可能な薬品貯槽を備える薬品送出装置
CN106432490B (zh) * 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201084A (en) 1982-06-25 1985-10-11 New Zealand Dev Finance 4-carboxamidoacridine derivatives and pharmaceutical compositions containing such
SG45403A1 (en) 1991-01-11 1998-01-16 Glaxo Lab Sa Acridine derivatives
US5663179A (en) * 1992-07-10 1997-09-02 Laboratoires Glaxo Sa Certain isoquinoline derivatives having anti-tumor properties
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
NZ295546A (en) 1994-10-05 1999-01-28 Glaxo Wellcome Inc Parenteral medicament containing n-{4-[2-1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}- 9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide, surfactant, and buffer
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
WO1998053811A1 (en) 1997-05-27 1998-12-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9710612D0 (en) * 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU755567B2 (en) 1998-02-05 2002-12-12 University Of Maryland At Baltimore Breast cancer resistance protein (BCRP) and the DNA which encodes it
WO1999065493A1 (en) 1998-06-18 1999-12-23 The George Washington University Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects
NZ509859A (en) 1998-08-05 2003-09-26 Aventis Pharma S Use of camptothecin derivatives, with reduced gastrointestinal toxicity
AU4955200A (en) * 1999-05-17 2000-12-05 Cancer Research Ventures Limited A method of improving bioavailability of orally administered drugs, a method of screening for enhancers of such bioavailability and novel pharmaceutical compositions for oral delivery of drugs
US6521635B1 (en) * 2000-01-20 2003-02-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of MXR transport by acridine derivatives

Also Published As

Publication number Publication date
ATE484295T1 (de) 2010-10-15
ES2270834T3 (es) 2007-04-16
CY1105795T1 (el) 2011-02-02
EP1749540A2 (de) 2007-02-07
DK1189637T3 (da) 2006-12-11
EP1749540A3 (de) 2007-05-30
US20060128743A1 (en) 2006-06-15
EP1189637B1 (de) 2006-08-23
DE60030283T2 (de) 2007-09-20
PT1189637E (pt) 2007-01-31
WO2000069390A3 (en) 2001-12-13
US20020128282A1 (en) 2002-09-12
US7030132B2 (en) 2006-04-18
AU4955200A (en) 2000-12-05
DE60045114D1 (de) 2010-11-25
DE60030283D1 (de) 2006-10-05
WO2000069390A2 (en) 2000-11-23
EP1749540B1 (de) 2010-10-13
EP1189637A2 (de) 2002-03-27

Similar Documents

Publication Publication Date Title
DE60030283D1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
CY1121133T1 (el) Τοπικα εφαρμοσιμο φαρμακευτικο παρασκευασμα
ATE339954T1 (de) Kombinationen von formoterol und tiotropium-salz
NZ324801A (en) Oral pharmaceutical dosage form containing taxol or etoposide derivatives and a bioenhancer compound
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
CY1118873T1 (el) Φαρμακευτικη δοσολογικη μορφη μιας φαρμακευτικα αποδεκτης ενωσης διαλυτοποιησης
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
DE69526428D1 (de) Verfahren zur erhöhung der bioverfügbarkeit oraler arzneimittel
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
ATE292453T1 (de) Antivirale arznei
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
EP1574215A4 (de) Feste arznei zur oralen verabreichung
DE60124144D1 (de) Pharmazeutische zusammenstellungen zur verstärkung der artzneimitteleffekte
SE9902742D0 (sv) New pharmaceutical formultion
ITMI992736A0 (it) Composizioni farmaceutiche per la somministrazione localizzata nel cav o orale di farmaci antiinfiammatori non stereoidei utili per la terapi
EA200602199A1 (ru) Композиции, содержащие глюкозаминогликан и нестероидное противовоспалительное средство
GT200100223A (es) Composiciones hidroliticamente inestables.
ECSP993090A (es) Composicion farmaceutica de proteinas erizo y su uso

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1189637

Country of ref document: EP